Indian Equities Conclude Week in Positive Territory Amidst USIran Diplomacy
SpaceX Scrubs Starship Test Flight Reschedules for Friday Amid IPO BuildUp
HS2s Cost Ballooning to 1027bn and Delays to 2039 Raise Fresh Questions Over UK Infrastructure Spending
Tulsi Gabbard Resigns as US Intelligence Chief Amid Iran Strike Considerations
Gold Prices Steady Near 4500 as Market Watches IranUS Peace Talks
Puerto Ricos Top 2026 Travel Destinations Old San Juan and Vieques Highlighted as Tourism Drivers
HHH Q1 2026 Earnings Earnings Per Share Beat Estimates by 73 Stock Declines Slightly
RPRX Q1 2026 Earnings EPS Beat Drives Positive Stock Movement
Nutrien NTR Q1 2026 Earnings EPS Miss Amidst Fertilizer Market Pressures
ALOY Q1 2024 Earnings WiderthanExpected Loss Raises Concerns Despite Stock Uptick
Energy Transfer ET Q1 2026 Earnings Mixed Results with EPS Miss but Slight Stock Uptick
SU Q1 2026 Earnings Strong EPS Beat Reflects Operational Discipline
Structure Therapeutics GPCR Edges Higher on Modest Gains Testing Key Resistance Levels
ADTRAN Holdings ADTN Surges 523 as Stock Approaches Key Resistance Level
Nuveen Municipal Credit Opportunities Fund NMCO Edges Higher Amid Steady Income Demand
Vital Farms VITL Edges Higher Amid Steady Trading Key Levels in Focus
Genesco GCO Edges Higher as Stock Tests Key Resistance Levels
Indonesian Commodity Exporters Raise Concerns Over Proposed State Monopoly
EXP Q1 2026 Earnings Powerful EPS Beat Highlights Cost Discipline Amid Subdued Demand
Highview Merger Corp Holds Steady at 1012 Amid Minimal Movement
GSBC Q1 2026 Earnings Strong EPS Beat Despite Slight Stock Decline
CocaCola Consolidated Inc COKE Q1 2026 Earnings Solid EPS Amid Quiet Quarter
OCGN Q1 2026 Earnings EPS Miss Highlights Ongoing Cash Burn as Pipeline Advances
Sera Prognostics Q1 2026 Earnings EPS In Line with Estimates as Stock Rises 15
GBFH Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Stock Declines
WMT Q1 2026 Earnings Modest EPS Miss Amidst Stable Operations
Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances